Abstracts tagged "IL-1"

Abstract Number: 2714 • 2013 ACR/ARHP Annual Meeting
Commensal Intestinal Microbiota Drives Spontaneous Interleukin-1- and T Helper 17-Mediated Arthritis In Mice
Shahla Abdollahi-Roodsaz¹, Rebecca Rogier², Tom Ederveen², Harm Wopereis³, Raish Oozeer³, Marije I. Koenders² and Wim B. van den Berg¹, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Danone Research, Wageningen, Netherlands
Background/Purpose: Altered composition of intestinal microbiota in recent-onset rheumatoid arthritis (RA) and possible efficacy of oral antibiotics suggest a role of intestinal microbiota in RA.…
Abstract Number: 2188 • 2013 ACR/ARHP Annual Meeting
Role of Interleukin-1 in Abnormal Monocyte Phenotype in Systemic Onset Juvenile Idiopathic Arthritis
Yujuan Zhang^1,2, Claudia Macaubas², Clarissa Klein³, M. Virginia Pascual⁴, Arielle Hay⁵, Susan D. Thompson⁶, Christy I. Sandborg³, Norman T. Ilowite⁷ and Elizabeth D. Mellins⁸, ¹Pediatrics, Stanford University Med Ctr, Palo Alto, CA, ²Pediatric Rheumatology, Stanford University Med Ctr, Stanford, CA, ³Stanford University Med Ctr, Stanford, CA, ⁴Baylor Institue for Immunology Research, Dallas, TX, ⁵The Children's Hospital at Montefiore, Bronx, NY, ⁶Department of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ⁸Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA
Background/Purpose: Monocytes undergo phenotype changes when exposed to different microenvironments: the classic proinflammatory M1 phenotype, alternative regulatory M2 phenotype and M2-like phenotype, are each regulated…
Abstract Number: 1887 • 2013 ACR/ARHP Annual Meeting
Interleukin-1 Receptor Antagonist (IL-1Ra) Plasma Levels Predict Radiographic Progression Of Symptomatic Knee Osteoarthritis Over 24 Months
Mukundan Attur¹, Alexander Statnikov^2,3, Jonathan Samuels⁴, Svetlana Krasnokutsky¹, Jeffrey D. Greenberg¹, Zhiguo Li², Leon Rybak⁵, Constantin F. Aliferis^2,6 and Steven B. Abramson⁷, ¹Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ²Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, NY, ³Division of Translational Medicine, NYU Langone Medical Center, New York, NY, ⁴Division of Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY, ⁵Department of Radiology, NYU Langone Medical Center, New York, NY, ⁶Department of Pathology, NYU Langone Medical Center, New York, NY, ⁷Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY
Background/Purpose: Osteoarthritis is multi-factorial complex degenerative joint disease that leads to permanent joint damage. We and others have shown elevated levels of inflammatory and anti-inflammatory…
Abstract Number: 1780 • 2013 ACR/ARHP Annual Meeting
The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Norman T. Ilowite¹, Kristi Prather², Yuliya Lokhnygina³, Laura E. Schanberg⁴, Melissa Elder⁵, Diana Milojevic⁶, James W. Verbsky⁷, Steven J. Spalding⁸, Yukiko Kimura⁹, Lisa F. Imundo¹⁰, Marilynn G. Punaro¹¹, David D. Sherry¹², Stacey E. Tarvin¹³, Lawrence S. Zemel¹⁴, James D. Birmingham¹⁵, Beth S. Gottlieb¹⁶, Michael L. Miller¹⁷, Kathleen M. O'Neil¹⁸, Natasha M. Ruth¹⁹, Carol A. Wallace²⁰, Nora G. Singer²¹ and Christy I. Sandborg²², ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Statistics, Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Pediatrics, University of Florida, Gainesville, HI, ⁶Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁸Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹⁴Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH, ¹⁵Medicine & Pediatrics, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ¹⁶Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁷Rheumatology, Childrens Memorial Hospital, Chicago, IL, ¹⁸Division of Pediatric Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ²⁰University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²²Pediatric Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The RAndomized Placebo Phase Study Of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT) is a multicenter controlled trial using a…
Abstract Number: 1194 • 2013 ACR/ARHP Annual Meeting
Enhanced IL-1β and IL-6 Production In Gout Patients Upon Stimulation With Mono Sodium Urate Crystals and Synergizing Agents Compared To Healthy Volunteers
Tania O. Crisan¹, Maartje Cleophas¹, Mihai G. Netea¹, Tim L. Jansen² and Leo A. Joosten³, ¹Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: Gout is an autoinflammatory disease characterized by the deposition of monosodium urate (MSU) crystals in the joints of hyperuricaemic patients and subsequent attacks of…
Abstract Number: 1205 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Canakinumab In a Cryopyrin-Associated Periodic Syndrome Cohort.A Single Center Experience
Virginia Moreira-Navarrete¹, Francisco Javier Toyos Saenz de Miera², Carmen Vargas Lebrón³ and F. Navarro Sarabia⁴, ¹Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ²Hospital Virgen de la Macarena, Sevilla, Spain, ³Hospital Virgen Macarena, SEVILLA, Spain, ⁴Rheumatologist Service, Hospital Universitario Virgen Macarena, Sevilla, Spain
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) comprises a group of rare, but severe, autoinflammatory diseases, characterized by urticaria, periodic fever, central nervous system inflammation, arthropathy, and…
Abstract Number: 1206 • 2013 ACR/ARHP Annual Meeting
Canakinumab Treatment Regimens In CAPS Patients
Ferdinand Hofer¹, Theresa Endres¹, Birgit Kortus-Goetze², Norbert Blank³, Elisabeth Weissbarth-Riedel⁴, Catharina Schuetz⁵, Tilmann Kallinich⁶, Karoline Krause⁷, Christoph Rietschel⁸, Gerd Horneff⁹ and Jasmin B. Kuemmerle-Deschner¹⁰, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²Klinik für Innere Medizin, Klinikum der Philipps-Universität Marburg, Marburg, Germany, ³University of Heidelberg, Heidelberg, Germany, ⁴Kinderrheumatologische Ambulanz, Universitätsklinikum Eppendorf, Hamburg, Germany, ⁵Klinik für Kinder und Jugendmedizin, Universitätsklinikum Ulm, Ulm, Germany, ⁶Charite, University Medicine Berlin, Berlin, Germany, ⁷Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁸Kinder- und Jugendrheumatologie, Clementine-Kinderhospital, Frankfurt, Germany, ⁹Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁰University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Canakinumab is a recombinant monoclonal fully human antibody against Interleukin-1β and approved for the treatment of CAPS in many countries including Europe and the…
Abstract Number: 1213 • 2013 ACR/ARHP Annual Meeting
Low-Penetrance NLRP3-Variants
Theresa Endres¹, Ferdinand Hofer¹, Raphaela T. Goldbach-Mansky², Hal M. Hoffman³, Norbert Blank⁴, Karoline Krause⁵, Christoph Rietschel⁶, Gerd Horneff⁷, Peter Lohse⁸ and Jasmin B. Kuemmerle-Deschner⁹, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Division of Allergy, Immunology and Rheumatology, University of California at San Diego, La Jolla, CA, ⁴University of Heidelberg, Heidelberg, Germany, ⁵Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁶Kinder- und Jugendrheumatologie, Clementine-Kinderhospital, Frankfurt, Germany, ⁷Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁸Institut für Laboratoriumsmedizin und Humangenetik, Singen, Germany, ⁹University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) presents as rare, autosomal dominant disease spectrum, due to mutations in the NLRP3-gene which lead to excessive interleukin-1 (IL-1) release.…
Abstract Number: 1165 • 2013 ACR/ARHP Annual Meeting
Systems Approach To The Study Of the Microbiome and Inflammatory Pathways In Oral Ulcer Tissue From Patients With Active Behςet’s Syndrome (BS)
Cailin Sibley¹, Gulen Hatemi², Yusuf Yazici³, Yin Liu⁴, Steve Brooks⁵, Hasan Yazici⁶ and Raphaela Goldbach-Mansky⁷, ¹Office of the Clinical Director, NIH / NIAMS, Bethesda, MD, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Translational Autoinflammatory Disease Section, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁵NIAMS/NIH, Bethesda, MD, ⁶Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ⁷Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: Behcet's syndrome (BS) exhibits features of both innate and acquired immunity. Oral ulceration is the cardinal lesion which usually precedes other manifestations. Despite the…
Abstract Number: 57 • 2013 ACR/ARHP Annual Meeting
Role Of Procatabolic Cytokines In Dysregulation Of O-Linked N-Acetylglucosamine Modified Proteins In Human Osteoarthritic Chondrocytes
Raquel Largo¹, Ane Larranaga-Vera², Sandra Pérez-Baos², Gabriel Herrero-Beaumont² and Jessica Andrés-Bergós^2,3, ¹Bone and Joint Research Unit, IIS, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ²Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz. UAM, Madrid, Spain, ³Tissue Engineering Repair and Regeneration Program, Hospital for Special Surgery and Weill Cornell Medical College, New York, NY
Background/Purpose: Nuclear and cytoplasmic protein glycosylation by the addition of O-linked N-Acetylglucosamine (O-GlcNAc) to serine and threonine residues is a widespread post-translational modification that has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].